MRC1 and carcinoma: As shown in Figure 1H, mRNA of Arginase1, CD206, Trem2 (triggering receptor expressed on myeloid cells 2) and Ym1, which are typical M2 markers, were significantly reduced upon embelin treatment at carcinoma stage (day 85).